Abstract
Industrial production of veterinary vaccines started in the 1950s introducing the possibility to vaccinate millions of animals. In the meantime veterinary vaccines and mass vaccination became a necessary prerequisite for a modern livestock industry. Nearly all current veterinary vaccines worldwide are conventional vaccines, killed or modified live vaccines. Until now, the only animal infection eradicated by vaccination is rinderpest, and for numerous pathogens no effective and safe vaccine is available. There is an undisputed urgent need to develop novel vaccination strategies with improved efficacy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alexandrescu DT, Ichim TE, Riordan NH, Marincola FM, Di Nardo A, Kabigting FD, Dasanu CA (2010) Immunotherapy for melanoma: current status and perspectives. J Immunother 33(6):570–590
Bergman PJ (2007) Canine oral melanoma. Clin Tech Small Anim Pract 22(2):55–60
Bergman PJ, Wolchok JD (2008) Of mice and men (and dogs): development of a xenogeneic DNA vaccine for canine oral malignant melanoma. Cancer Ther 6:817–826
Bergman PJ, Camps-Palau MA, McKnight JA, Leibman NF, Craft DM, Leung C, Liao J, Riviere I, Sadelain M, Hohenhaus AE, Gregor P, Houghton AN, Perales MA, Wolchok JD (2006) Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the animal medical center. Vaccine 24(21):4582–4585
Bowern N, Ramshaw IA, Badenoch-Jones P, Doherty PC (1984) Effect of an iron-chelating agent on lymphocyte proliferation. Aust J Exp Biol Med Sci 62(Pt 6 (6241825)):743–754
Brault AC (2009) Changing patterns of West Nile virus transmission: altered vector competence and host susceptibility. Vet Res 40(2):43
Bunning ML, Fox PE, Bowen RA, Komar N, Chang GJ, Speaker TJ, Stephens MR, Nemeth N, Panella NA, Langevin SA, Gordy P, Teehee M, Bright PR, Turell MJ (2007) DNA vaccination of the American crow (Corvus brachyrhynchos) provides partial protection against lethal challenge with West Nile virus. Avian Dis 51(2):573–577
Burkitt D (1958) A sarcoma involving the jaws in African children. Br J Surg 46(197):218–223
Canadian food inspection agency – VBS File # 870VV/I4.0/A8 (2005) Environmental assessment for licensing infectious haematopoietic necrosis virus vaccine, DNA vaccine in Canada. http://www.inspection.gc.ca/english/anima/vetbio/eaee/vbeaihnve.shtml. Accessed 25th september 2007
Davis BS, Chang GJ, Cropp B, Roehrig JT, Martin DA, Mitchell CJ, Bowen R, Bunning ML (2001) West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 75(9):4040–4047
D.A. Grosenbaugh et al. 2010 Multicenter clinical trial with a xenogeneic DNA vaccine administered as an adjunct treatment for canine oral malignant melanoma following surgical excision of the primary tumor. Am J Vet Res (submitted)
Garver KA, Conway CM, Elliott DG, Kurath G (2005) Analysis of DNA-vaccinated fish reveals viral antigen in muscle, kidney and thymus, and transient histopathologic changes. Mar Biotechnol NY 7(5):540–553
Giese M (1998) DNA-antiviral vaccines: new developments and approaches – a review. Virus Genes 17(3):219–232
Giese M, Bahr U, Jakob NJ, Kehm R, Handermann M, Muller H, Vahlenkamp TH, Spiess C, Schneider TH, Schusse G, Darai G (2002) Stable and long-lasting immune response in horses after DNA vaccination against equine arteritis virus. Virus Genes 25(2):159–167
Kanduc D (2009) “Self-nonself” peptides in the design of vaccines. Curr Pharm Des 15(28):3283–3289
Liao JC, Gregor P, Wolchok JD, Orlandi F, Craft D, Leung C, Houghton AN, Bergman PJ (2006) Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun 6:8
Lunney JK, Benfield DA, Rowland RR (2010) Porcine reproductive and respiratory syndrome virus: an update on an emerging and re-emerging viral disease of swine. Virus Res 154(1–2):1–6
Meeusen EN, Walker J, Peters A, Pastoret PP, Jungersen G (2007) Current status of veterinary vaccines. Clin Microbiol Rev 20(3):489–510; table of contents
Mortensen S, Stryhn H, Sogaard R, Boklund A, Stark KD, Christensen J, Willeberg P (2002) Risk factors for infection of sow herds with porcine reproductive and respiratory syndrome (PRRS) virus. Prev Vet Med 53(1–2):83–101
Murray KO, Mertens E, Despres P (2010) West Nile virus and its emergence in the United States of America. Vet Res 41(6):67
NCT00106769 (2008) Vaccine to prevent West Nile virus disease. http://www.clinicaltrials.gov/ct2/show/NCT00106769
Neagu M, Constantin C, Tanase C (2010) Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma. Expert Rev Mol Diagn 10(7):897–919
Nieto K, Gissmann L, Schädlich L (2010) Human papillomavirus-specific immune therapy: failure and hope. Antivir Ther 15(7):951–957
Ostrand-Rosenberg S (2008) Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 18(1):11–18
Redding L, Weiner DB (2009) DNA vaccines in veterinary use. Expert Rev Vaccin 8(9):1251–1276
Roeder PL, Taylor WP (2002) Rinderpest. Vet Clin North Am Food Anim Pract 18(3):515–547, ix
Saksida SM (2006) Infectious haematopoietic necrosis epidemic (2001 to 2003) in farmed Atlantic salmon Salmo salar in British Columbia. Dis Aquat Organ 72(3):213–223
Shindo M, Yoshida Y (2010) Regulatory T cells and skin tumors. Recent Pat Inflamm Allergy Drug Discov 4(3):249–254
Shoieb AM, Donnell RL, Seaman R (2009) Oral malignant squamo-melanocytic tumor in a dog. J Vet Dent 26(4):234–237
Stingl G, Brocker EB, Mertelsmann R, Wolff K, Schreiber S, Kampgen E, Schneeberger A, Dummer W, Brennscheid U, Veelken H, Birnstiel ML, Zatloukal K, Schmidt W, Maass G, Wagner E, Baschle M, Giese M, Kempe ER, Weber HA, Voigt T (1996) Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene. Hum Gene Ther 7(8800750):551–563
Tobiasch E, Kehm R, Bahr U, Tidona CA, Jakob NJ, Handermann M, Darai G, Giese M (2001) Large envelope glycoprotein and nucleocapsid protein of equine arteritis virus (EAV) induce an immune response in Balb/c mice by DNA vaccination; strategy for developing a DNA-vaccine against EAV-infection. Virus Genes 22(2):187–199
Traxler GS, Anderson E, LaPatra SE, Richard J, Shewmaker B, Kurath G (1999) Naked DNA vaccination of Atlantic salmon Salmo salar against IHNV. Dis Aquat Organ 38(3):183–190
USDA (2010) USDA licenses DNA vaccine for treatment of melanoma in dogs. J Am Vet Med Assoc 236(5):495
USDA-APHIS-VS-CVB (2008) Veterinary biological products licensees and permittees. http://www.aphis.usda.gov/animal_health/vet_biologics/publications/CurrentProdCodeBook.pdf Accessed 25th september 2007
van Kempen LC, van Muijen GN, Ruiter DJ (2007) Melanoma progression in a changing environment. Eur J Cell Biol 86(2):65–67
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag/Wien
About this chapter
Cite this chapter
Giese, M. (2012). Approved Veterinary Vaccines: Paving the Way to Products for Human Health. In: Thalhamer, J., Weiss, R., Scheiblhofer, S. (eds) Gene Vaccines. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0439-2_13
Download citation
DOI: https://doi.org/10.1007/978-3-7091-0439-2_13
Published:
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-0438-5
Online ISBN: 978-3-7091-0439-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)